Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-08-14 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-11 | Biosergen | Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-11 | Biosergen | Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-07 | Biosergen | Biosergen AB: Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Biosergen | Biosergen AB: Biosergen will present at Aktiespararnas Småbolagsdagarna June 13, 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-31 | Biosergen | Bulletin from the annual general meeting on 31 May 2023 in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Biosergen | Biosergen AB: Biosergen publishes 2022 annual report | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Biosergen | Notice of annual general meeting in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Notice of annual general meeting in Biosergen ABRight to participate and notice of participation Shareholders wishing to participate in the annual general meeting must:
Trustee-registered shares Shareholders whose shares are registered in the name of a bank or other nominee or trustee must, to be able to exercise their voting rights at the annual general meeting, request the trustee to register their shares in their own name with Euroclear Sweden AB (so-called ”voting rights registration”). Such voting rights registration must be implemented by the trustee no later than Thursday 25 May 2023. Accordingly, shareholders must notify their trustee and request such voting rights registration well before this date. Proxy etc. A proxy representing a shareholder must bring a valid written power of attorney to the annual general meeting that is dated and signed by the shareholder. The power of attorney shall not be dated more than one year before the date of the annual general meeting, unless it specifically stipulates that it will remain valid and in effect for a longer period of time (but not longer than five years). Should the power of attorney be issued by a legal entity, a copy of a registration certificate (Sw. registreringsbevis) or equivalent document shall be presented at the meeting. In order to facilitate the preparations before the meeting, a copy of the power of attorney and other proof of authority should be attached to the notice of participation submitted in advance. A template power of attorney can be found at the company’s website (www.biosergen.net) and will be sent by mail to the shareholders who request it and state their address. Proposed agenda 1. Opening of the meeting. 10. Determination of the number of board members and deputies as well as auditors and deputy auditors. Proposed resolutions Item 1: Election of chairman of the meeting Major shareholders propose that lawyer Gustav Johansson is elected as chairman of the meeting. Item 8 b: Resolution on allocation of the company’s result according to the adopted balance sheet The board of directors proposes that no dividend is paid and that available funds are carried forward to a new account. Item 9: Determination of the number of board members and deputies as well as auditors and deputy auditors Major shareholders propose that five ordinary board members, without deputies, are elected until the end of the next annual general meeting. Major shareholders further propose that one registered public accounting firm, without deputies, is appointed as auditor until the end of the next annual general meeting. Item 10: Determination of fees for the board of directors and the auditors Major shareholders propose that remuneration to the board shall be paid with EUR 40,000 to the chairman of the board (unchanged since previous year) and with EUR 25,000 to each of the other board members who are not employed by the company (unchanged since previous year). Major shareholders further propose that remuneration to the auditor shall be paid in accordance with customary norms and approved invoice. Item 11: Election of the board of directors and auditor Major shareholders propose that Torsten Goesch, Achim Kaufhold, Marianne Kock, Henrik Moltke, and Mattias Klintemar are re-elected as ordinary board members. Furthermore, major shareholders propose re-election of Torsten Goesch as chairman of the board. The current board members Lena Degling Wikingsson and Hanne Mette Dyrlie Kristensen have declined re-election. Information on the board members who are proposed for re-election can be found in the annual report and at the company website (www.biosergen.net). Major shareholders finally propose that Öhrlings PricewaterhouseCoopers AB is re-elected as auditor. Öhrlings PricewaterhouseCoopers AB has informed that Johan Engstam will continue to be appointed as the responsible auditor. Item 12: Resolution on issue authorisation The board of directors proposes that the annual general meeting resolves to authorise the board of directors, up until the next annual general meeting, at one or several occasions, with or without deviation from the shareholders’ preferential rights and with or without provisions regarding contribution in kind, set-off or other conditions, to issue shares, convertibles and/or warrants. The reason for why a deviation from the shareholders’ preferential rights should be possible is to enable the company to source working capital, to be able to execute acquisitions of companies or operating assets as well as to enable new issues to industrial partners within the framework of partnerships and alliances. In case the authorisation is used for a new issue with deviation from the shareholders’ preferential rights, the issue shall be made on market terms. Item 13: Resolution on amendment of the articles of association The board of directors proposes that the annual general meeting resolves to amend the company’s articles of association as follows: § 7 Bolagsstämma / General meetings Current wording Aktieägare som vill deltaga i förhandlingarna på bolagsstämma ska anmäla detta till bolaget senast den dag som anges i kallelsen till stämman. Sistnämnda dag får inte vara söndag, annan allmän helgdag, lördag, midsommarafton, julafton eller nyårsafton och inte infalla tidigare än femte vardagen före stämman. Proposed wording Aktieägare som vill deltaga i förhandlingarna på bolagsstämma ska anmäla detta till bolaget senast den dag som anges i kallelsen till stämman. Sistnämnda dag får inte vara söndag, annan allmän helgdag, lördag, midsommarafton, julafton eller nyårsafton och inte infalla tidigare än femte vardagen före stämman. Bolagsstämma ska hållas i Solna, Stockholm eller Malmö. Particular majority requirements For valid resolutions on the proposals pursuant to items 12 and 13, the proposals have to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the meeting. Disclosures at the annual general meeting Shareholders present at the annual general meeting have the right to request information in accordance with Chapter 7, Section 32 of the Swedish Companies Act (2005:551). Meeting documents Accounting documents, complete proposals and other documents before the annual general meeting will be available at the company’s office, Fogdevreten 2, SE-171 65 Solna, Sweden and at the company’s website (www.biosergen.net) as from no later than three weeks before the annual general meeting, and will also be sent to shareholders who request it and state their address. Copies of the documents will also be available at the annual general meeting. Number of shares and votes in the company As of the date of this notice to attend the annual general meeting, the total number of shares and votes in the company amounts to 42 427 660. The company does not hold any own shares. Processing of personal data For information on how your personal data is processed, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf . ___________________ Solna in April 2023 Biosergen AB (publ) |
||||
2023-04-05 | Biosergen | Biosergen AB: Biosergen - Reduced risk after positive phase 1-studies - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Biosergen | Biosergen AB: Biosergen - Minskad risk efter positiva fas 1-studier - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for fourth quarter 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-03-29 | Carlsquare | Carlsquare: Mrkt BUZZ, Biosergen: Plans for speedy development of lead candidate | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-29 | Biosergen | Biosergen AB: Biosergen provides Phase 2 clinical development strategy update | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-28 | Biosergen | Biosergen AB: Biosergen will be participating in Investerarträff arranged by Financial Stockholm, March 29 | Pressreleaser | Visa Stäng |
|
||||
2023-03-21 | Biosergen | Biosergen AB: Biosergen will be participating at Mangold Insight Investor Day, March 22 | Pressreleaser | Visa Stäng |
|
||||
2023-03-21 | Biosergen | Biosergen AB: Carlsquare has initiated its coverage of Biosergen | Pressreleaser | Visa Stäng |
|
||||
2023-03-20 | Carlsquare | Carlsquare: Initiation of coverage, Biosergen: Make antifungals great again | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-13 | Biosergen | Biosergen AB: Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-24 | Biosergen | Biosergen AB: Biosergen - Fungicide with potential - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-24 | Biosergen | Biosergen AB: Biosergen - Svampdödare med potential - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-16 | Biosergen | Biosergen AB: Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-12-12 | Biosergen | Biosergen AB: The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-30 | Biosergen | Biosergen AB: Biosergen publishes interim report for third quarter 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-10-20 | Biosergen | Biosergen AB: Biosergen's warrants of series TO2 are admitted to trading | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-19 | Biosergen | Biosergen AB: Biosergen allocates shares to an underwriter in connection with the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-05 | Biosergen | Biosergen AB: Biosergen appoints Mangold Fondkommission to act as a liquidity provider | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-10-04 | Biosergen | Biosergen AB: Biosergen announces the outcome in the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-26 | Biosergen | Biosergen AB: Mangold Insight publishes interview with Biosergen's CEO | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-22 | Biosergen | Biosergen AB: Members of the board of directors and executive management subscribe in ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-15 | Biosergen | Biosergen AB: The subscription period in Biosergen's rights issue starts today | Pressreleaser | Visa Stäng |
|
||||
2022-09-08 | Biosergen | Biosergen AB: Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-02 | Biosergen | Biosergen AB: Biosergen's Board of Directors decides on a rights issue of units of approximately SEK 60.2 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for second quarter 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-31 | Biosergen | Biosergen AB: Biosergen receives a loan of SEK 7 million to finance continued development | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Biosergen | Biosergen AB: Biosergen completes the third cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|